



ASX Announcement

C-Pulse™ Pilot Clinical Trial Abstract accepted by CSANZ

Sydney, Australia – 10 May 2007: Sunshine Heart, Inc (ASX: SHC) announced today that an abstract of the C-Pulse™ Pilot Clinical Trial has been reviewed and accepted by the Abstract Grading Subcommittee of the Cardiac Society of Australia and New Zealand (CSANZ) Council.

Entitled *“First-in-human study of a novel implantable extra-ascending aortic counterpulsation pump (C-Pulse™) in patients with end-stage heart failure”*, the abstract includes data from the C-Pulse™ Pilot Clinical Trial, conducted across multiple clinical trial sites in Australia and New Zealand. This trial data is the foundation of the C-Pulse™ safety and performance to be presented to the USA Food and Drug Administration (FDA) and the US Medical Centers to position the US Clinical Trial which is scheduled to commence in 2007.

Data from the Pilot Clinical Trial will be presented at the Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand to be held 9-12 August, 2007 in Christchurch, New Zealand.

At this meeting, it is expected that the medical team will present data from the trial demonstrating:

- Safety of implant surgery
- Improvements in the patients' heart function, and
- Improvements in patient quality of life following implantation

The authors of the abstract include Drs. Paget Milsom, Peter Ruygrok, William Peters and Malcolm Legget of Auckland City Hospital; Drs. Paul Jansz and Christopher Hayward of St Vincent's Hospital, Sydney; Drs. Gerry O'Driscoll and Robert Larbalastier of Royal Perth Hospital; and Drs. Julian Smith and Betty Ho of Southern Health Monash Medical Centre.

For further information, please visit www.sunshineheart.com or contact:

Media

Daniella Goldberg PhD
+612 9237 2803 / 0416 211 067
dgoldberg@bcg.com.au

Sunshine Heart

Victor Windeyer
Chief Operating Officer
+61 2 8424 7700
victor.windeyer@sunshineheart.com

Don Rohrbaugh
Chief Executive Officer
+1 714 665 1951
don.rohrbaugh@sunshineheart.com

Brian Bolton
Chief Financial Officer
+61 2 8424 7700
brian.bolton@sunshineheart.com

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company's filings with the Australian Stock Exchange.

About Sunshine Heart

Sunshine Heart (ASX: SHC) (www.sunshineheart.com) is a global medical device company, committed to the commercialization of C-Pulse™ an implantable, non-blood contacting, mechanical heart assist device for the treatment of people with heart failure. Sunshine Heart listed on the ASX in September 2004 and has a presence in Australia, New Zealand and the United States of America.